中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2012, Vol. 7 ›› Issue (11): 862-866.

• 原著:周围神经损伤修复保护与再生 • 上一篇    下一篇

Department of Rheumatism, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China

  

  • 收稿日期:2011-12-24 修回日期:2012-03-10 出版日期:2012-04-15 发布日期:2012-04-15

Department of Rheumatism, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China

Naizhi Wang, Yingying Guo, Lili Yang, Wenyi Fu, Yanbing Xu, Linxin Hou, Shuai Zhao, Ning Zhang   

  1. Department of Rheumatism, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China
  • Received:2011-12-24 Revised:2012-03-10 Online:2012-04-15 Published:2012-04-15
  • Contact: Ning Zhang, M.D., Chief physician, Professor, Department of Rheumatism, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China zhangning@sj-hospital.org
  • About author:Naizhi Wang★, Master, Department of Rheumatism, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China

PDF

979

Abstract:

In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1-2 years post-treatment (mean 16 months). The incidence of peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 8.8% (7/80), which was significantly higher than the conventional treatment group (2.6%; 4/156). The relative risk of developing peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 3.41 (95% confidence interval: 1.03-11.31). Comparison of the tumor necrosis factor inhibitors revealed that etanercept and infliximab had no significant difference in terms of inducing peripheral neuropathy. Experimental findings indicate that tumor necrosis factor inhibitors may increase the risk of peripheral neuropathy.

Key words: tumor necrosis factor inhibitors, adverse reactions, peripheral neuropathy, rheumatoid arthritis, cohort study, risk factors